Product Name :
TBOPP
Description:
TBOPP is a selective inhibitor of DOCK1 with an IC50 of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (Kd of 7.1 μM), has anti-tumor activity for broader types of tumors.
CAS:
1996629-79-8
Molecular Weight:
490.49
Formula:
C24H21F3N2O4S
Chemical Name:
1-{2-oxo-2-[3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl]ethyl}-5-(pyrrolidine-1-sulfonyl)-1,2-dihydropyridin-2-one
Smiles :
O=S(=O)(C1=CN(CC(=O)C2C=CC(=CC=2)C2=CC(=CC=C2)C(F)(F)F)C(=O)C=C1)N1CCCC1
InChiKey:
ZMPDEBWNVHAKBB-UHFFFAOYSA-N
InChi :
InChI=1S/C24H21F3N2O4S/c25-24(26,27)20-5-3-4-19(14-20)17-6-8-18(9-7-17)22(30)16-28-15-21(10-11-23(28)31)34(32,33)29-12-1-2-13-29/h3-11,14-15H,1-2,12-13,16H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Talquetamab} MedChemExpress|{Talquetamab} CD3|{Talquetamab} Technical Information|{Talquetamab} In stock|{Talquetamab} custom synthesis|{Talquetamab} Autophagy}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
TBOPP is a selective inhibitor of DOCK1 with an IC50 of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (Kd of 7.1 μM), has anti-tumor activity for broader types of tumors.|Product information|CAS Number: 1996629-79-8|Molecular Weight: 490.49|Formula: C24H21F3N2O4S|Chemical Name: 1-{2-oxo-2-[3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl]ethyl}-5-(pyrrolidine-1-sulfonyl)-1,2-dihydropyridin-2-one|Smiles: O=S(=O)(C1=CN(CC(=O)C2C=CC(=CC=2)C2=CC(=CC=C2)C(F)(F)F)C(=O)C=C1)N1CCCC1|InChiKey: ZMPDEBWNVHAKBB-UHFFFAOYSA-N|InChi: InChI=1S/C24H21F3N2O4S/c25-24(26,27)20-5-3-4-19(14-20)17-6-8-18(9-7-17)22(30)16-28-15-21(10-11-23(28)31)34(32,33)29-12-1-2-13-29/h3-11,14-15H,1-2,12-13,16H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 100 mg/mL (203.{{3,3′-Diindolylmethane} MedChemExpress|{3,3′-Diindolylmethane} Androgen Receptor|{3,3′-Diindolylmethane} Protocol|{3,3′-Diindolylmethane} Description|{3,3′-Diindolylmethane} supplier|{3,3′-Diindolylmethane} Cancer} 88 mM; Need ultrasonic).PMID:23771862 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|TBOPP (12.5 µM; 3 days; 3LL cells) treatment inhibits DOCK1-mediated invasion, macropinocytosis, and survival under the condition of glutamine deprivation without impairing the biological functions of the closely related DOCK2 and DOCK5 proteins.|In Vivo:|TBOPP (0.67 mg per mouse; administrated on days 0, 1, 3, and 5; for 2 weeks; C57BL/6 mice) treatment effectively suppresses metastasis of cancer cells in vivo and the number of lymphocytes in the spleen is not changed, the body weight is also unchanged between TBOPP-treated and non-treated mice.|Products are for research use only. Not for human use.|